|1.||Hewison, Martin: 15 articles (10/2014 - 03/2003)|
|2.||Feldman, David: 15 articles (01/2014 - 11/2002)|
|3.||Malloy, Peter J: 13 articles (01/2014 - 11/2002)|
|4.||Mathieu, Chantal: 11 articles (05/2015 - 12/2004)|
|5.||Holick, Michael F: 10 articles (09/2013 - 01/2005)|
|6.||Fukumoto, Seiji: 10 articles (07/2012 - 05/2002)|
|7.||Goltzman, David: 9 articles (07/2012 - 03/2003)|
|8.||Hollis, Bruce W: 9 articles (09/2011 - 04/2004)|
|9.||Fukagawa, Masafumi: 8 articles (01/2013 - 01/2002)|
|10.||Fujita, Toshiro: 8 articles (11/2010 - 05/2002)|
|1.||Hypercalcemia (Milk Alkali Syndrome)
04/01/2014 - "Previous studies have demonstrated an association between granulomatous disorders and hypercalcemia, the purported mechanism of which is extrarenal production of 1,25-dihydroxyvitamin D by activated macrophages. "
01/01/1999 - "To determine whether the rat hindlimb elevation model can be used to study the effects of spaceflight and loss of gravitational loading on bone in the adult animal, and to examine the effects of age on bone responsiveness to mechanical loading, we studied 6-mo-old rats subjected to hindlimb elevation for up to 5 wk. Loss of weight bearing in the adult induced a mild hypercalcemia, diminished serum 1,25-dihydroxyvitamin D, decreased vertebral bone mass, and blunted the otherwise normal increase in femoral mass associated with bone maturation. "
01/01/2014 - "The responsible mechanism of hypercalcemia in this setting has been described to be secondary to 1,25-dihydroxyvitamin D secretion. "
08/01/2012 - "1,25-Dihydroxyvitamin D-mediated hypercalcemia is responsive to glucocorticoid therapy."
08/01/2012 - "A case of severe 1,25-dihydroxyvitamin D-mediated hypercalcemia due to a granulomatous disorder."
|2.||Prostatic Neoplasms (Prostate Cancer)
11/01/2010 - "1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells."
12/01/2009 - "Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer."
03/01/2007 - "1,25-Dihydroxyvitamin D (1,25D) inhibits growth of prostate cancer cells and has been proposed to play a protective role in prostate cancer. "
12/01/1997 - "Endocrine factors produced by prostate cancer cells affect both phosphate and 1,25-dihydroxyvitamin D metabolisms. "
09/01/1995 - "Epidemiologic and experimental data support a role for 1,25-dihydroxyvitamin D(3) in the growth regulation of prostate cancer. "
|3.||Chronic Kidney Failure (Chronic Renal Failure)
08/01/2013 - "The present study suggests that the decrease of 1,25-dihydroxyvitamin D and the accumulation of uremic toxins contributed to the decreased hepatic clearance of CYP3A4 substrates in patients with end-stage renal disease. "
11/01/1998 - "The lack of a GH-induced increase in 1,25-dihydroxyvitamin D levels, probably due to treatment with alpha-calcidol, might be linked to the absence of a response in BMD during GH treatment in children with chronic renal failure."
06/17/1988 - "[Decreased production of 1,25-dihydroxyvitamin D in patients with chronic kidney failure]."
12/01/1984 - "The circulating concentrations of 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D are abnormally low in patients with chronic renal failure (CRF). "
10/01/1995 - "In 8 patients in whom follow-up data were available, post-treatment serum phosphate and 1,25-dihydroxyvitamin D levels improved in the setting of stable mild renal insufficiency; only one patient developed end-stage renal failure after 20 years, suggesting that these patients do not invariably progress rapidly to renal failure. "
12/01/2007 - "Intravenous administration of Mg not only improved these electrolyte abnormalities but also increased serum levels of intact PTH, bone formation markers, 1,25-dihydroxyvitamin D, as well as bone resorption markers in the urine, and lowered urinary phosphate reabsorption. "
01/01/2012 - "The local synthesis of 1,25-dihydroxyvitamin D within bone is necessary to modulate bone resorption and promote bone formation. "
01/01/2006 - "1,25-Dihydroxyvitamin D(3) has a pivotal role in bone resorption and osteoclast activity. "
10/01/1995 - "Osteoblasts from the toothless (osteopetrotic) mutation in the rat are unable to direct bone resorption by normal osteoclasts in response to 1,25-dihydroxyvitamin D."
04/01/1990 - "These data indicate that lower mobility in the elderly leads to higher bone resorption, which may suppress the formation of 1,25-dihydroxyvitamin D."
10/01/1995 - "Osteomalacia associated with adult acquired Fanconi's syndrome is thought to result from hypophosphataemia and relative 1,25-dihydroxyvitamin D deficiency. "
02/01/1987 - "[Serum concentrations of 1,25-dihydroxyvitamin D in cases of osteomalacia, parathyroid dysfunction and idiopathic hypercalciuria]."
03/01/1982 - "Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia."
11/01/1980 - "Thus, in the present study, we investigated the potential role of abnormal vitamin D metabolism in the pathogenesis of this disorder and the effect of 1,25-dihydroxyvitamin D(3) therapy on both the biochemical abnormalities characteristic of this disease and the osteomalacia. "
08/01/1979 - "An unique form of osteomalacia associated with end organ refractoriness to 1,25-dihydroxyvitamin D and apparent defective synthesis of 25-hydroxyvitamin D."
|5.||Cholecalciferol (Vitamin D3)
|7.||Parathyroid Hormone (Parathormone)
|4.||Heterologous Transplantation (Xenotransplantation)